High Quality Metformin HCl CAS 1115-70-4 Powder Fast Shipping Best Price

Metformin hydrochloride More Info

Introduction
Metformin hydrochloride (CAS No. 1115-70-4) is a synthetic biguanide-class compound and the gold-standard first-line therapy for type 2 diabetes mellitus (T2DM) worldwide. Discovered in the 1920s and clinically approved in the mid-20th century, it has become one of the most widely prescribed medications due to its proven efficacy, favorable safety profile, and broad metabolic regulatory effects. Unlike insulin or sulfonylureas, metformin does not stimulate insulin secretion; instead, it targets the root causes of T2DM, including insulin resistance and excessive hepatic glucose production. Beyond T2DM management, it is approved for polycystic ovary syndrome (PCOS) in many regions and is actively investigated for potential applications in non-alcoholic fatty liver disease (NAFLD), obesity, and age-related metabolic disorders. Its low cost, minimal hypoglycemia risk, and cardioprotective properties make it an indispensable tool in metabolic disease care.
Mechanism of Action
Core Metabolic Regulatory Mechanisms
Metformin exerts its glucose-lowering and metabolic effects through a multitargeted mechanism, primarily acting on the liver, skeletal muscle, adipose tissue, and gastrointestinal tract:
Inhibition of Hepatic Gluconeogenesis
The primary mechanism involves suppressing glucose production and release by the liver. Metformin blocks key enzymes in the gluconeogenesis pathway (e.g., phosphoenolpyruvate carboxykinase, glucose-6-phosphatase) and reduces hepatic sensitivity to glucagon—a hormone that promotes glucose synthesis. This directly lowers fasting blood glucose levels, a hallmark of T2DM.
Enhancement of Peripheral Insulin Sensitivity
It improves insulin-mediated glucose uptake and utilization in skeletal muscle and adipose tissue by activating the AMP-activated protein kinase (AMPK) pathway—a central regulator of cellular energy metabolism. AMPK activation increases the translocation of glucose transporter 4 (GLUT4) to the cell membrane, enabling tissues to efficiently uptake glucose from the bloodstream.
Reduction of Intestinal Glucose Absorption
Metformin slows the absorption of dietary glucose in the proximal small intestine, delaying postprandial blood glucose spikes. This effect is partially mediated by inhibiting intestinal brush-border enzymes (e.g., α-glucosidases) and modulating gut microbiota composition to favor glucose-lowering bacterial strains.
Modulation of Incretin Hormones
It stimulates the secretion of glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances insulin secretion, suppresses glucagon release, and promotes satiety. This further augments its glucose-lowering and weight-management effects.
AMPK-Mediated Metabolic Regulation
As a key cellular energy sensor, AMPK activation by metformin also inhibits hepatic lipogenesis, promotes fatty acid oxidation in muscle, and suppresses pro-inflammatory signaling pathways—contributing to its benefits in NAFLD and metabolic syndrome.
Pharmacological Effects & Advantages
Key Pharmacological Effects
Hypoglycemic Activity
Effectively lowers both fasting and postprandial blood glucose levels without causing hypoglycemia when used as monotherapy. It reduces glycated hemoglobin (HbA1c) by 1–2% in T2DM patients, a clinically significant reduction associated with decreased long-term diabetes complications.
Weight Management Benefits
Unlike many antidiabetic drugs (e.g., sulfonylureas, insulin) that often cause weight gain, metformin typically results in mild weight loss (1–3 kg) or weight neutrality. This is attributed to reduced appetite, decreased intestinal calorie absorption, and increased energy expenditure.
Metabolic Syndrome Improvement
It ameliorates all core components of metabolic syndrome, including insulin resistance, hyperglycemia, dyslipidemia (reduces triglycerides and LDL cholesterol, increases HDL cholesterol), and modest blood pressure reduction.
Hepatoprotective Effects
Reduces hepatic steatosis and inflammation in NAFLD and non-alcoholic steatohepatitis (NASH) by inhibiting lipogenesis and promoting fatty acid oxidation, slowing disease progression and reducing liver fibrosis risk.
Cardioprotective Properties
Clinically proven to reduce the risk of major adverse cardiovascular events (MACE)—including myocardial infarction, stroke, and cardiovascular death—in T2DM patients. It is the only oral antidiabetic agent with robust long-term cardioprotective evidence.
PCOS-Related Efficacy
Improves insulin resistance in PCOS patients, restoring ovulatory function, reducing menstrual irregularities, and lowering circulating androgen levels (e.g., testosterone), which alleviates symptoms like hirsutism and acne.
Key Advantages
Minimal Hypoglycemia Risk
Does not stimulate insulin secretion, so the risk of life-threatening hypoglycemia is extremely low—even in elderly patients or those with mild renal impairment.
Favorable Safety Profile
Long-term use is well-tolerated, with no evidence of carcinogenicity, mutagenicity, or reproductive toxicity at therapeutic doses.
Cost-Effectiveness
Generic formulations are widely available at low cost, ensuring global accessibility for patients with T2DM.
Broad Patient Applicability
Suitable for adults, adolescents (≥10 years old with T2DM), and pregnant women (for PCOS or gestational diabetes under medical supervision).
Multitargeted Metabolic Benefits
Addresses the underlying pathophysiology of T2DM and offers additional benefits beyond glucose control, supporting overall metabolic health.
Clinical & Practical Applications
1. Approved Indications
Type 2 Diabetes Mellitus
Monotherapy for patients with inadequate glycemic control via lifestyle modifications (diet, exercise).
Combination therapy with other antidiabetic agents (e.g., sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, insulin) when monotherapy is insufficient.
Pediatric use approved for patients ≥10 years old with T2DM.
Polycystic Ovary Syndrome (PCOS)
Treatment of insulin resistance-related symptoms, including anovulation, menstrual irregularities, and infertility.
Adjunctive therapy for hirsutism and acne associated with elevated androgens.
Gestational Diabetes Mellitus (GDM)
Second-line therapy (after insulin) for glycemic control in pregnant women with GDM who do not respond to dietary modifications.
2. Investigational Applications
NAFLD/NASH: Leading candidate for treating NAFLD and NASH, with clinical trials showing significant reductions in hepatic fat, inflammation, and fibrosis.
Prediabetes: Recommended by clinical guidelines to prevent or delay progression from prediabetes to T2DM in high-risk individuals (e.g., obese adults, those with a family history of T2DM).
Obesity: Investigated as an adjunct to lifestyle interventions for weight loss, particularly in obese patients with insulin resistance.
Aging-Related Conditions: Preclinical and clinical studies explore its potential to extend healthspan by modulating AMPK and reducing cellular senescence.
Cancer Prevention: Emerging evidence suggests it may reduce the risk of certain cancers (e.g., colorectal, breast, pancreatic) in T2DM patients, possibly via AMPK activation and inhibition of cancer cell metabolism.
3. Administration & Dosing Considerations
Routes of Administration: Oral, available as immediate-release tablets/capsules, extended-release tablets, and oral solution.
Dosing Guidelines
Immediate-release: Start at 500 mg orally twice daily (with meals) or 850 mg once daily, titrated gradually (every 1–2 weeks) to minimize gastrointestinal side effects. Maximum daily dose: 2550 mg (divided into 2–3 doses).
Extended-release: Start at 500 mg once daily (with the evening meal), titrated to 1000–2000 mg once daily. Ideal for patients with gastrointestinal intolerance to immediate-release formulations.
Pediatric (10–17 years): Start at 500 mg twice daily, titrated to a maximum of 2000 mg/day based on weight and glycemic response.
Special Populations
Renal impairment: Dose adjustment required for estimated glomerular filtration rate (eGFR) 30–45 mL/min/1.73m²; avoid use if eGFR <30 mL/min/1.73m² due to lactic acidosis risk.
Hepatic impairment: Use with caution in mild to moderate hepatic dysfunction; avoid in severe liver disease.
Elderly patients: Initiate with lower doses and monitor renal function regularly.
Handling & Storage
Storage Conditions: Store at 25°C (77°F) in a dry, cool place, protected from light and moisture. Keep containers tightly sealed to prevent degradation. Oral solutions should be stored at 4–25°C and used before the expiration date.
Handling Precautions
Administer with meals to reduce gastrointestinal irritation. Swallow extended-release tablets whole—do not crush, chew, or split, as this may increase side effects or reduce efficacy.
Avoid concurrent use with excessive alcohol, as this increases the risk of lactic acidosis.
No special protective equipment is required for routine handling, but wash hands after contact with tablets or solutions. Avoid eye contact; rinse thoroughly with water if exposure occurs.
Disposal: Dispose of unused or expired medication in accordance with local pharmaceutical waste regulations. Do not discard in household waste or wastewater.
Limitations & Research Updates
Limitations
Gastrointestinal Side Effects
Common initial side effects include diarrhea, nausea, abdominal discomfort, and bloating (occurring in 10–20% of patients). These are usually mild, transient, and reduce with dose titration or switching to extended-release formulations.
Lactic Acidosis Risk
A rare but serious adverse event (incidence <0.01%) associated with drug accumulation in patients with severe renal impairment, hypoxia, severe infection, or excessive alcohol intake. Symptoms include muscle pain, weakness, respiratory distress, and metabolic acidosis, requiring immediate medical intervention.
Vitamin B12 Deficiency
Long-term use (≥5 years) may reduce intestinal absorption of vitamin B12, leading to deficiency. Routine monitoring of vitamin B12 levels is recommended for patients on chronic therapy.
Contraindications
Not suitable for patients with severe renal/hepatic impairment, metabolic acidosis, severe infection, or hypersensitivity to metformin.
Limited Efficacy in Advanced T2DM
May require combination therapy with other antidiabetic agents as T2DM progresses and pancreatic β-cell function declines.
Research Updates
Novel Formulations
Oral films, nanoparticle-based delivery systems, and inhalable formulations are being developed to improve bioavailability, reduce gastrointestinal side effects, and enhance patient adherence.
Fixed-Dose Combinations
Approved combinations with SGLT2 inhibitors (e.g., metformin + dapagliflozin) or GLP-1 receptor agonists (e.g., metformin + semaglutide) offer synergistic glycemic control, weight loss, and cardioprotective benefits.
Expanded Indications
Clinical trials are ongoing to confirm efficacy in NASH (potential regulatory approval in the near future) and to explore its role in Alzheimer’s disease (via metabolic modulation) and cancer therapy.
Mechanism Elucidation
Ongoing research is uncovering additional molecular targets, including its effects on gut microbiota and epigenetic regulation, which may explain its broad metabolic benefits beyond glucose control.
Personalized Medicine
Studies are investigating genetic factors (e.g., OCT1 transporter polymorphisms) that influence metformin response to optimize dosing and improve therapeutic outcomes for individual patients.

Product Image

FAQ

Q1. Can I get a free sample?

We can send you a samll free sample, and you only need to pay for the shipping cost.

Q2. What is the HyperChem payment term?

T/T in advance
LC at sight
DP at sight

Bank transfer

PayPal

Bitcoin...

Q3. What is HyperChem shipment policy?

Our policy is to strive for the quickest shipment time possible.

For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.

Q4. What is HyperChem shipment term?

By Express  
FedEx  UPS  DHL  EMS                               
Fast: 3-7 days around, high cost, door to door service

By Air                                        
Suitable for more than 50kg 
Fast: 3-7 days, hight cost, port to port, professional broker needed 

By Sea
Suitable for more than 500kg      
Fast: 7-45 days, low cost, port to port, professional broker needed 

We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.

Q5. What HyperChem will provide after shipment?

For sample orders: 
After shipment is done, an timely email including:

1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice

For commercial orders:
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.